Visar resultat 1 - 5 av 20 avhandlingar innehållade ordet B-ALL.
Sammanfattning : Acute lymphoblastic leukemia (ALL) is a highly aggressive pediatric cancer that can affect both B cells and T cells. The advent of new therapies has increased the cure rates for both B-ALL and T-ALL patients. However, some patients still experience relapse with a variable response to the treatment and display poor survival. LÄS MER
Sammanfattning : Leukotrienes (LT) are biologically active metabolites of the fatty acid arachidonic acid (AA). After liberation of AA by phospholipase A 2 (PLA 2), this fatty acid can be converted to leukotrienes, lipoxins, prostaglandins or thromboxane. The conversion of AA to LTA 4 is catalyzed by five-lipoxygenase (5-LO). LÄS MER
Sammanfattning : By virtue of the role of G1-phase cyclin proteins as regulators of differentiation, proliferation, and apoptosis, their improper expression can lead to altered cellular homeostasis and tumor formation. Cyclins provide the regulatory partner for cyclin-cdk complexes whose enzymatic activity drives cell cycle progression. LÄS MER
Sammanfattning : This thesis deals with the metabolism of arachidonic acid via the 5-lipoxygenase- and the 15- lipoxygenase-1 pathways in normal and malignant hematopoietic cells. The first part of the thesis (papers I & II) describes the expression of genes involved in arachidonic acid metabolism and the capacity to generate leukotriene (LT) B4 via the 5-lipoxygenase pathway in blood tumor cells from patients with precursor B-ALL (acute lymphoblastic leukemia) and AML (acute myeloid leukemia). LÄS MER
5. Detection of immunoglobulin heavy chain gene rearrangement with PCR for MRD analysis in lymphoproliferative disorders
Sammanfattning : Immunoglobulin heavy chain (IGH) gene rearrangement occurs during early B-lymphocyte differentiation, assembling the different IGH gene segments to a functional gene, which can serve as a marker for study of lineage association and detection of Minimal Residual Disease (MRD) in clonal diseases deriving from B-lymphocytes or their early differentiation stages. Use of a molecular marker for the leukemic cells could help improve treatment by monitoring therapeutic efficacy, predicting relapse, and identifying very small amounts of tumour cells contaminating autografts after purging or enrichment of stem cells. LÄS MER